Bioincept

About Bioincept

Bioincept, LLC operates as a clinical-stage biotechnology firm focused on developing therapeutic and diagnostic products centered around the Pre-Implantation Factor (PIF). Founded in 2001 by Eytan Barnea and Jacqueline Barnea, the company is built on the discovery that viable mammalian embryos secrete PIF, a peptide essential for implantation, immune modulation, and pregnancy maintenance. The core of Bioincept's strategy is to leverage the broad regulatory functions of PIF, which are naturally involved in pregnancy, immunity, and inflammation, for wider therapeutic applications.

The company's primary business involves the development of a synthetic analogue of PIF (sPIF) to translate its natural effects into clinical treatments. This has led to a diversified development pipeline targeting autoimmunity, neuro-regeneration, transplantation, and oncology. For instance, Bioincept has explored sPIF for improving outcomes in in-vitro fertilization (IVF) by promoting embryo development and preventing demise caused by embryo-toxic factors. The company has secured significant non-dilutive funding, including over $10 million in U.S. government grants, to support its research. Its funding history also includes multiple venture capital and seed rounds, with an initial angel round in 2007.

Bioincept's main product candidate is its synthetic PIF, developed under cGMP standards. The firm has successfully completed a Phase 1 clinical safety study and has received orphan drug designations for the prevention of graft-vs-host disease and acute radiation syndrome. The company's intellectual property is protected by a robust global patent estate. By focusing on the unique properties of PIF to modulate immunity and promote tissue regeneration, Bioincept aims to address significant unmet medical needs across various disease areas, positioning itself as a key player in regenerative medicine.